Matthew P Akerman (Mathew P Akerman)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Human Serum Albumin

Gas Chromatography Mass Spectrometry

Top Venues

Dalton transactions (Cambridge, England : 2003)

RSC medicinal chemistry

Inorganic chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Sheldon Sookai, Matthew P Akerman, Orde Q Munro
Chiral Au(III) chelates exhibit unique NCI-60 cytotoxicity profiles and interactions with human serum albumin. Dalton transactions (Cambridge, England : 2003) 53 (11) (2024)
Sheldon Sookai, Matthew P Akerman, Orde Q Munro
Chiral Au(III) chelates exhibit unique NCI-60 cytotoxicity profiles and interactions with human serum albumin. Dalton transactions (Cambridge, England : 2003) 53 (11) (2024)
Sheldon Sookai, Matthew P Akerman, Orde Q Munro
Chiral Au(III) chelates exhibit unique NCI-60 cytotoxicity profiles and interactions with human serum albumin. Dalton transactions (Cambridge, England : 2003) (2024)
Gciniwe S Mathenjwa, Abir Chakraborty, Abantika Chakraborty, Ronel Muller, Matthew P Akerman, Moira L Bode, Adrienne L Edkins, Clinton G L Veale
Rationally modified SNX-class Hsp90 inhibitors disrupt extracellular fibronectin assembly without intracellular Hsp90 activity. RSC medicinal chemistry (2024)
Temidayo Oyetunde, Siphamandla Masikane, Malik Dilshad Khan, Matthew P Akerman, Helmar Görls, Neerish Revaprasadu, Winfried Plass
Precursor Engineering for the Synthesis of Mixed Anionic Metal (Cu, Mn) Chalcogenide Nanomaterials via Solvent-Less Synthesis. Inorganic chemistry 61 (17) (2022)
Kristy-Lyn Barry, Craig D Grimmer, Orde Q Munro, Matthew P Akerman
Self-assembled supramolecular structures of O , N , N ' tridentate imidazole-phenol Schiff base compounds. RSC advances 10 (13) (2020)
Clinton G L Veale, Janeeka Jayram, Shivani Naidoo, Dustin Laming, Tarryn Swart, Tania Olivier, Matthew P Akerman, Katherine A de Villiers, Heinrich C Hoppe, Vineet Jeena
Insights into structural and physicochemical properties required for β-hematin inhibition of privileged triarylimidazoles. RSC medicinal chemistry 11 (1) (2019)